Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395296 | 1.00 | MEN1 (0.56) | MEN1KMT2AACEALDH1A1TSHR | |
| SCHEMBL31053868 | 0.79 | CYP3A4 (0.77) | ALDH1A1NPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL1171492 | 0.79 | CYP3A4 (0.77) | ALDH1A1NPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL31171638 | 0.76 | ACE (0.58) | ACEALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL31171631 | 0.76 | ACE (0.58) | ACEALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL19326702 | 0.76 | MEN1 (0.61) | MEN1KMT2AALDH1A1TSHRNPC1 | |
| SCHEMBL19326700 | 0.76 | MEN1 (0.61) | MEN1KMT2AALDH1A1TSHRNPC1 | |
| SCHEMBL6800842 | 0.74 | ACE (0.61) | ACEALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL16798976 | 0.74 | HSD17B10 (0.59) | MEN1KMT2AALDH1A1TSHRNPC1 | |
| SCHEMBL11343509 | 0.74 | HPGD (0.60) | MEN1KMT2AACEALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844366-B2 | Sulfonamide hydroxamates | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | disclosed |
| US-6787559-B2 | HYDROXYCARBONYL OR ALKYLOXYCARBONYL OR AMINOHYDROXYCARBONYL SUBSTITUTED SULFONAMIDE COMPOUNDS USEFUL AS PROCOLLAGEN C-PROTENASE INHIBITOR | SYNTEX (U.S.A.) LLC. | 2004-09-07 | — | — | US | disclosed |
| EP-1149072-B1 | SULFONAMIDE HYDROXAMATES | HOFFMANN LA ROCHE (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | BILLLEDEAU ROLAND JOSEPH (US) | 2003-11-20 | — | — | US | disclosed |
| US-20030199520-A1 | Sulfonamide hydroxamates | BILLLEDEAU ROLAND JOSEPH (US) | 2003-10-23 | — | — | US | disclosed |
| US-6492394-B1 | PROCOLLAGEN C-PROTEINASE INHIBITORS; TREATING FIBROTIC DISEASES | SYNTEX (U.S.A.) LLC | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216405-A1 | Hydroxycarbonyl or alkyloxycarbonyl or aminohydroxycarbonyl substituted sulfonamide compounds useful as procollagen C-protenase inhibitor | CTSE, PREP, HPN | MEN1 3614/4885KMT2A 2264/4885ACE 111/4885 |
| US-20030199520-A1 | Sulfonamide hydroxamates | MMP3, TIMP3, MMP13 | MEN1 3717/4885KMT2A 1614/4885ACE 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.